8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Medulloblastoma Associated with Down Syndrome: From a Rare Event Leading to a Pathogenic Hypothesis

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Down syndrome (DS) is the most common chromosome abnormality with a unique cancer predisposition syndrome pattern: a higher risk to develop acute leukemia and a lower incidence of solid tumors. In particular, brain tumors are rarely reported in the DS population, and biological behavior and natural history are not well described and identified. We report a case of a 10-year-old child with DS who presented with a medulloblastoma (MB). Histological examination revealed a classic MB with focal anaplasia and the molecular profile showed the presence of a CTNNB1 variant associated with the wingless (WNT) molecular subgroup with a good prognosis in contrast to our case report that has shown an early metastatic relapse. The nearly seven-fold decreased risk of MB in children with DS suggests the presence of protective biological mechanisms. The cerebellum hypoplasia and the reduced volume of cerebellar granule neuron progenitor cells seem to be a possible favorable condition to prevent MB development via inhibition of neuroectodermal differentiation. Moreover, the NOTCH/WNT dysregulation in DS, which is probably associated with an increased risk of leukemia, suggests a pivotal role of this pathway alteration in the pathogenesis of MB; therefore, this condition should be further investigated in future studies by molecular characterizations.

          Related collections

          Most cited references43

          • Record: found
          • Abstract: found
          • Article: not found

          Molecular subgroups of medulloblastoma: the current consensus

          Medulloblastoma, a small blue cell malignancy of the cerebellum, is a major cause of morbidity and mortality in pediatric oncology. Current mechanisms for clinical prognostication and stratification include clinical factors (age, presence of metastases, and extent of resection) as well as histological subgrouping (classic, desmoplastic, and large cell/anaplastic histology). Transcriptional profiling studies of medulloblastoma cohorts from several research groups around the globe have suggested the existence of multiple distinct molecular subgroups that differ in their demographics, transcriptomes, somatic genetic events, and clinical outcomes. Variations in the number, composition, and nature of the subgroups between studies brought about a consensus conference in Boston in the fall of 2010. Discussants at the conference came to a consensus that the evidence supported the existence of four main subgroups of medulloblastoma (Wnt, Shh, Group 3, and Group 4). Participants outlined the demographic, transcriptional, genetic, and clinical differences between the four subgroups. While it is anticipated that the molecular classification of medulloblastoma will continue to evolve and diversify in the future as larger cohorts are studied at greater depth, herein we outline the current consensus nomenclature, and the differences between the medulloblastoma subgroups.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Subtypes of medulloblastoma have distinct developmental origins

            Medulloblastoma encompasses a collection of clinically and molecularly diverse tumor subtypes that together comprise the most common malignant childhood brain tumor1–4. These tumors are thought to arise within the cerebellum, with approximately 25% originating from granule neuron precursor cells (GNPCs) following aberrant activation of the Sonic Hedgehog pathway (hereafter, SHH-subtype)3–8. The pathological processes that drive heterogeneity among the other medulloblastoma subtypes are not known, hindering the development of much needed new therapies. Here, we provide evidence that a discrete subtype of medulloblastoma that contains activating mutations in the WNT pathway effector CTNNB1 (hereafter, WNT-subtype)1,3,4, arises outside the cerebellum from cells of the dorsal brainstem. We found that genes marking human WNT-subtype medulloblastomas are more frequently expressed in the lower rhombic lip (LRL) and embryonic dorsal brainstem than in the upper rhombic lip (URL) and developing cerebellum. Magnetic resonance imaging (MRI) and intra-operative reports showed that human WNT-subtype tumors infiltrate the dorsal brainstem, while SHH-subtype tumors are located within the cerebellar hemispheres. Activating mutations in Ctnnb1 had little impact on progenitor cell populations in the cerebellum, but caused the abnormal accumulation of cells on the embryonic dorsal brainstem that included aberrantly proliferating Zic1+ precursor cells. These lesions persisted in all mutant adult mice and in 15% of cases in which Tp53 was concurrently deleted, progressed to form medulloblastomas that recapitulated the anatomy and gene expression profiles of human WNT-subtype medulloblastoma. We provide the first evidence that subtypes of medulloblastoma have distinct cellular origins. Our data provide an explanation for the marked molecular and clinical differences between SHH and WNT-subtype medulloblastomas and have profound implications for future research and treatment of this important childhood cancer.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.

              Historical risk stratification criteria for medulloblastoma rely primarily on clinicopathological variables pertaining to age, presence of metastases, extent of resection, histological subtypes and in some instances individual genetic aberrations such as MYC and MYCN amplification. In 2010, an international panel of experts established consensus defining four main subgroups of medulloblastoma (WNT, SHH, Group 3 and Group 4) delineated by transcriptional profiling. This has led to the current generation of biomarker-driven clinical trials assigning WNT tumors to a favorable prognosis group in addition to clinicopathological criteria including MYC and MYCN gene amplifications. However, outcome prediction of non-WNT subgroups is a challenge due to inconsistent survival reports. In 2015, a consensus conference was convened in Heidelberg with the objective to further refine the risk stratification in the context of subgroups and agree on a definition of risk groups of non-infant, childhood medulloblastoma (ages 3-17). Published and unpublished data over the past 5 years were reviewed, and a consensus was reached regarding the level of evidence for currently available biomarkers. The following risk groups were defined based on current survival rates: low risk (>90 % survival), average (standard) risk (75-90 % survival), high risk (50-75 % survival) and very high risk (<50 % survival) disease. The WNT subgroup and non-metastatic Group 4 tumors with whole chromosome 11 loss or whole chromosome 17 gain were recognized as low-risk tumors that may qualify for reduced therapy. High-risk strata were defined as patients with metastatic SHH or Group 4 tumors, or MYCN-amplified SHH medulloblastomas. Very high-risk patients are Group 3 with metastases or SHH with TP53 mutation. In addition, a number of consensus points were reached that should be standardized across future clinical trials. Although we anticipate new data will emerge from currently ongoing and recently completed clinical trials, this consensus can serve as an outline for prioritization of certain molecular subsets of tumors to define and validate risk groups as a basis for future clinical trials.
                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Journal
                Diagnostics (Basel)
                Diagnostics (Basel)
                diagnostics
                Diagnostics
                MDPI
                2075-4418
                07 February 2021
                February 2021
                : 11
                : 2
                : 254
                Affiliations
                [1 ]Department of Pediatrics, Sapienza University, Viale Regina Elena 324, 00161 Rome, Italy; lale.boni88@ 123456gmail.com (A.B.); ranalli.marco91@ 123456gmail.com (M.R.)
                [2 ]Department of Onco-Hematology and Cell and Gene Therapy, Bambino Gesù Children’s Hospital IRCCS, Piazza Sant’Onofrio 4, 00146 Rome, Italy; giada.delbaldo@ 123456opbg.net (G.D.B.); roberto.carta@ 123456opbg.net (R.C.); mariachiara.lodi@ 123456opbg.net (M.L.); antonella.cacchione@ 123456opbg.net (A.C.); evelina.miele@ 123456opbg.net (E.M.); iside.alessi@ 123456opbg.net (I.A.); annamaria.caroleo@ 123456opbg.net (A.M.C.); mantonietta.deioris@ 123456opbg.net (M.A.D.I.)
                [3 ]Laboratory of Medical Genetics, IRCCS Bambino Gesù Children’s Hospital, Piazza Sant’Onofrio 4, 00146 Rome, Italy; emanuele.agolini@ 123456opbg.net (E.A.); martina.rinelli@ 123456opbg.net (M.R.); viola.alesi@ 123456opbg.net (V.A.)
                [4 ]Pediatric and Infectious Disease Unit, Bambino Gesù Children’s Hospital, IRCCS, Piazza Sant’Onofrio 4, 00146 Rome, Italy; diletta.valentini@ 123456opbg.net
                [5 ]Department of Laboratories, Pathology Unit, Bambino Gesù Children’s Hospital, Piazza Sant’Onofrio 4, 00146 Rome, Italy; sabrina.rossi@ 123456opbg.net
                [6 ]Neuroradiology Unit, Department of Imaging, Bambino Gesù Children’s Hospital, IRCCS, Piazza Sant’Onofrio 4, 00146 Rome, Italy; gstefania.colafati@ 123456opbg.net
                [7 ]School of Nursing, College of Behavioral, Social and Health Sciences, Clemson University, Clemson, SC 29634, USA; lboccuto@ 123456clemson.edu
                [8 ]JC Self Research Institute of the Greenwood Genetic Center, Greenwood, SC 29646, USA
                [9 ]Department of Imaging, Radiation Oncology and Haematology, Policlinico A. Gemelli Fundation, IRCCS, Catholic University of Sacred Heart, Largo A. Gemelli 1, 00168 Rome, Italy; mario.balducci@ 123456policlinicogemelli.it
                [10 ]Neurosurgery Unit, Department of Neurological and Psychiatric Sciences, Bambino Gesù Children’s Hospital, IRCCS, Piazza Sant’Onofrio 4, 00146 Rome, Italy; andrea.carai@ 123456opbg.net
                Author notes
                [* ]Correspondence: angela.mastronuzzi@ 123456opbg.net ; Tel.: +39-0668594664; Fax: +39-0668592292
                Author information
                https://orcid.org/0000-0002-8723-7224
                https://orcid.org/0000-0001-6543-6225
                https://orcid.org/0000-0001-7514-5683
                https://orcid.org/0000-0002-4747-1032
                https://orcid.org/0000-0003-1249-7301
                https://orcid.org/0000-0002-2113-4505
                https://orcid.org/0000-0002-5203-7855
                https://orcid.org/0000-0002-4408-2373
                Article
                diagnostics-11-00254
                10.3390/diagnostics11020254
                7915142
                33562188
                57861ee8-a71b-4b72-9b02-d744ac4b97f0
                © 2021 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 08 January 2021
                : 01 February 2021
                Categories
                Case Report

                brain tumor,down syndrome,medulloblastoma,cancer predisposition syndrome

                Comments

                Comment on this article